Influence of the selenium level on overall survival in lung cancer

Pietrzak, S.; Wójcik, Janusz; Scott, Rodney J.; Kashyap, Aniruddh; Grodzki, Tomasz; Baszuk, Piotr; Bielewicz, Michał; Marciniak, Wojciech; Wójcik, Norbert; Dębniak, Tadeusz; Masojć, Bartłomiej; Pieróg, Jarosław; Cybulski, Cezary; Gronwald, Jacek; Wojtyś, Małgorzata; Kubisa, Bartosz; Sukiennicki, Grzegorz; Deptuła, Jakub; Waloszczyk, Piotr; Jakubowska, Anna; Lubiński, Jan; Lener, Marcin

doi:10.1016/j.jtemb.2019.07.010

Cited by 25 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Poland, the mean serum selenium level among women is approximately 80-90 µg/L, compared to >130 µg/L in the United States [15,19]. We have reported a relationship between low serum selenium and the five year survival of patients with breast, lung and laryngeal cancer in Poland [20][21][22]. The objective of the current analysis is to report on the 10-year survival of experience of the breast cancer patients in our earlier cohort.…”

Section: Introductionmentioning

confidence: 95%

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

In a recent prospective study, we reported an association between a low serum selenium level and five-year survival among breast cancer patients. We now have updated the cohort to include 10-year survival rates. A blood sample was obtained from 538 women diagnosed with first primary invasive breast cancer between 2008 and 2015 in the region of Szczecin, Poland. Blood was collected before initiation of treatment. Serum selenium levels were quantified by mass spectroscopy. Each patient was assigned to one of four quartiles based on the distribution of serum selenium levels in the whole cohort. Patients were followed from diagnosis until death or last known alive (mean follow-up 7.9 years). The 10-year actuarial cumulative survival was 65.1% for women in the lowest quartile of serum selenium, compared to 86.7% for women in the highest quartile (p < 0.001 for difference). Further studies are needed to confirm the protective effect of selenium on breast cancer survival. If confirmed this may lead to an investigation of selenium supplementation on survival of breast cancer patients.

show abstract

Section: Introductionmentioning

confidence: 95%

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Besides low Se intake and inherited defects, many common diseases are also related to a suboptimal Se status in a more complex manner, where sometimes cause and consequences are difficult to disentangle [ 17 , 18 , 19 ]. A Se deficit is known to predispose to, e.g., liver or colorectal cancer [ 20 , 21 ], to thyroid [ 22 , 23 ] and cardiovascular disease [ 24 , 25 ], or to survival odds in sepsis [ 26 ], after poly-trauma [ 27 ], in breast [ 28 ], lung [ 29 ] or renal cancer [ 30 ]. Notably, the stringent interrelation between Se deficit and mortality risk may be confined to subjects residing in areas with low baseline Se supply, where a declining Se status may reach a certain essential minimal threshold more rapidly than under ample Se supply.…”

Section: Introductionmentioning

confidence: 99%

Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis

et al. 2020

View full text Add to dashboard Cite

Circulating selenoprotein P (SELENOP) constitutes an established biomarker of Se status. SELENOP concentrations are reduced in inflammation and severe disease. Recently, elevated SELENOP levels have been suggested as diagnostic marker and therapeutic target in pulmonary arterial hypertension (PAH). We decided to re-evaluate this hypothesis. A group of healthy controls (n = 30) was compared with patients suffering from systemic sclerosis (SSc, n = 66), one third with SSc-related PAH. Serum was analysed for trace elements and protein biomarkers, namely SELENOP, glutathione peroxidase 3 (GPx3) and ceruloplasmin (CP). Compared to controls, patients with SSc-related PAH displayed reduced serum Se (91 ± 2 vs. 68 ± 2 µg/L) and SELENOP concentrations (3.7 ± 0.8 vs. 2.7 ± 0.9 mg/L), along with lower GPx3 activity (278 ± 40 vs. 231 ± 54 U/L). All three biomarkers of Se status were particularly low in patients with skin involvement. Serum Cu was not different between the groups, but patients with SSc-related PAH showed elevated ratios of Cu/Se and CP/SELENOP as compared to controls. Our data indicate that patients with SSc-related PAH are characterized by reduced Se status in combination with elevated CP, in line with other inflammatory diseases. Further analyses are needed to verify the diagnostic value of these TE-related biomarkers in PAH.

show abstract

“…Sob a perspectiva clínica, 302 pacientes com câncer de pulmão foram acompanhados por 80 meses ou até o óbito. Os dados coletados sugerem um acréscimo na sobrevida global em pacientes em tratamento para câncer de pulmão que se encontram no estágio I da doença, e com níveis séricos de selênio acima de 69 µg/L no momento do diagnóstico (Pietrzak et al, 2019). Além disso, as propriedades protetoras dos compostos selênicos já se demonstraram aptas a combater até mesmo os efeitos colaterais induzidos por quimioterápicos clássicos (Rao & Rao, 1998).…”

Section: Câncer De Pulmãounclassified

Quimioprevenção e câncer no contexto brasileiro: Da higidez ao diagnóstico

Baptistella

Oliveira

Assunção

et al. 2021

RSD

View full text Add to dashboard Cite

O câncer representa um dos maiores problemas de saúde pública do mundo. Apesar dos avanços crescentes e de alguns sucessos ocasionais, pacientes e profissionais da saúde permanecem enfrentando diversos contratempos procedentes da terapia oncológica. Nesse sentido, a quimioprevenção é interessante, pois implica evitar o sofrimento causado pelo câncer, tendo potencial efeito antes do diagnóstico, no prognóstico e, também, no tratamento. Nesta revisão, teve-se como objetivo elencar as principais abordagens quimiopreventivas, a nível primário, secundário e terciário, para os tumores mais frequentes no Brasil e que possuem correlação com hábitos cotidianos adotados. Para isso, foi realizado um levantamento bibliográfico das publicações disponíveis nas bases da National Library of Medicine (NIH – PubMed) e Scholar Google dos últimos 20 anos. Utilizou-se os descritores: “chemoprevention”, “cancer chemoprevention” “non melanoma skin cancer”, “lung cancer”, “breast cancer”, e “colorectal cancer”. São notáveis os resultados obtidos por diversos estudos in vitro e in vivo, tal qual as histórias de sucesso clínico. Não obstante, os desafios ainda são muitos devido, sobretudo, às variáveis encontradas nas respostas individuais dos pacientes, as quais podem ser influenciadas por especificidades do quadro clínico, e entre outros fatores, como também as limitações de investimento e adesão. Futuras pesquisas e investimento em educação e conscientização do público em geral e de profissionais da saúde, a respeito dos benefícios por trás da quimioprevenção do câncer, possibilitariam a ampla aplicação da quimioprevenção e beneficiariam diversos âmbitos da saúde.

show abstract

Influence of the selenium level on overall survival in lung cancer

Cited by 25 publications

References 25 publications

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer

Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis

Quimioprevenção e câncer no contexto brasileiro: Da higidez ao diagnóstico

Contact Info

Product

Resources

About